EN-US Sun, 19 May 2013 20:17:06 -0400 157559 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J4SrjPQaXCU/ipo-market-heats-up-with-four-midsummer-deals-11-on-the-calendar-cm157559 News Headlines IPOs The IPO market exhibited strong signs of life this week when four companies were able to price , with three doing so above their initial ranges. Additionally, all four companies are trading<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/J4SrjPQaXCU" height="1" width="1"/> Sat, 21 Jul 2012 01:56:11 Z 2012-07-20T23:08:12Z Renaissance Capital CHUY DRTX FNDR KYAK PANW http://www.nasdaq.com/article/ipo-market-heats-up-with-four-midsummer-deals-11-on-the-calendar-cm157559 157320 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aaZB_E5B1Ds/durata-therapeutics-prices-ipo-at-9-below-the-range-cm157320 News Headlines IPOs Durata Therapeutics, which is developing a Phase 3 antibiotic candidate for acute skin infections, raised $68 million by offering 7.5 million shares at $9, below the range of $11 to $13.<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/aaZB_E5B1Ds" height="1" width="1"/> Thu, 19 Jul 2012 03:32:41 Z 2012-07-20T13:10:25Z Renaissance Capital DRTX http://www.nasdaq.com/article/durata-therapeutics-prices-ipo-at-9-below-the-range-cm157320 157331 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oBREU-A9aoc/5-us-ipos-planned-for-the-week-of-jul-16-cm157331 News Headlines IPOs The following IPOs are expected to price this week : Durata Therapeutics ( DRTX ), which is developing Phase 3 antibiotic candidate for acute skin infections, plans to raise $75 million<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/oBREU-A9aoc" height="1" width="1"/> Mon, 16 Jul 2012 16:00:07 Z 2012-07-20T13:12:49Z Renaissance Capital DRTX FIVE FNDR KYAK PANW http://www.nasdaq.com/article/5-us-ipos-planned-for-the-week-of-jul-16-cm157331 157340 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uOpJQmSRrwE/durata-therapeutics-sets-terms-for-75-million-us-ipo-cm157340 News Headlines IPOs Durata Therapeutics, a acquired rights from Pfizer to a Phase 3 candidate for the treatment of skin infections, announced terms for its IPO on Monday. The Morristown, NJ-based company plans to<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/uOpJQmSRrwE" height="1" width="1"/> Tue, 10 Jul 2012 01:14:07 Z 2012-07-20T13:13:47Z Renaissance Capital DRTX http://www.nasdaq.com/article/durata-therapeutics-sets-terms-for-75-million-us-ipo-cm157340